Production (Stage)
Sarepta Therapeutics, Inc.
SRPT
$37.60
-$1.01-2.62%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Total Cash And Short-Term Investments | 522.76M | 1.35B | 1.20B | 1.46B | 1.39B |
| Total Receivables | 724.52M | 649.73M | 515.99M | 392.26M | 419.38M |
| Inventory | 941.43M | 749.96M | 565.92M | 485.80M | 373.53M |
| Prepaid Expenses | 29.31M | 30.67M | 31.54M | 34.24M | 34.31M |
| Finance Division Loans and Leases Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Current Assets | -- | -- | -- | -- | -- |
| Other Current Assets | 214.51M | 288.32M | 373.53M | 310.87M | 246.90M |
| Total Current Assets | 2.43B | 3.07B | 2.69B | 2.68B | 2.46B |
|
|
|||||
| Total Current Assets | 2.43B | 3.07B | 2.69B | 2.68B | 2.46B |
| Net Property, Plant & Equipment | 507.65M | 488.65M | 446.69M | 400.20M | 375.57M |
| Long-term Investments | -- | -- | -- | -- | -- |
| Goodwill | -- | -- | -- | -- | -- |
| Total Other Intangibles | 26.20M | 26.89M | 27.57M | 28.25M | 28.93M |
| Finance Div Loans & Leases LT | -- | -- | -- | -- | -- |
| Total Finance Div Other LT Assets | -- | -- | -- | -- | -- |
| Total Other Assets | 235.51M | 237.30M | 253.82M | 304.56M | 313.64M |
| Total Assets | 3.47B | 3.96B | 3.60B | 3.42B | 3.22B |
|
|
|||||
| Total Accounts Payable | 156.11M | 214.44M | 118.77M | 107.42M | 91.54M |
| Total Accrued Expenses | 178.77M | 241.66M | 216.59M | 206.40M | 156.22M |
| Short-term Debt | -- | -- | -- | -- | -- |
| Current Portion of Long-Term Debt/Capital Leases | -- | -- | -- | -- | -- |
| Finance Division Debt Current | 12.97M | 13.27M | 108.88M | 108.63M | 121.86M |
| Total Finance Division Other Current Liabilities | 257.74M | 262.31M | 255.24M | 266.04M | 239.10M |
| Total Other Current Liabilities | 257.74M | 262.31M | 255.24M | 266.04M | 239.10M |
| Total Current Liabilities | 605.59M | 731.68M | 699.49M | 688.49M | 608.71M |
|
|
|||||
| Total Current Liabilities | 605.59M | 731.68M | 699.49M | 688.49M | 608.71M |
| Long-Term Debt | 1.14B | 1.14B | 1.14B | 1.13B | 1.13B |
| Short-term Debt | -- | -- | -- | -- | -- |
| Capital Leases | 205.46M | 192.47M | 170.01M | 143.60M | 140.10M |
| Finance Division Debt Non Current | -- | -- | -- | -- | -- |
| Total Finance Division Other Non Current Liabilities | -- | -- | -- | -- | -- |
| Total Other Liabilities | 373.33M | 374.15M | 373.40M | 380.29M | 380.72M |
| Total Liabilities | 2.32B | 2.44B | 2.38B | 2.35B | 2.26B |
|
|
|||||
| Common Stock & APIC | 5.80B | 5.74B | 5.59B | 5.48B | 5.37B |
| Retained Earnings | -4.66B | -4.21B | -4.37B | -4.40B | -4.41B |
| Treasury Stock & Other | 34.00K | -218.00K | 2.25M | -1.03M | -691.00K |
| Total Common Equity | 1.14B | 1.53B | 1.22B | 1.08B | 961.19M |
|
|
|||||
| Preferred Stock Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Non Redeemable | -- | -- | -- | -- | -- |
| Preferred Stock Convertible | -- | -- | -- | -- | -- |
| Preferred Stock, Others | -- | -- | -- | -- | -- |
| Total Preferred Equity | -- | -- | -- | -- | -- |
|
|
|||||
| Total Common Equity | 1.14B | 1.53B | 1.22B | 1.08B | 961.19M |
| Total Preferred Equity | -- | -- | -- | -- | -- |
| Total Minority Interest | -- | -- | -- | -- | -- |
| Total Equity | 1.14B | 1.53B | 1.22B | 1.08B | 961.19M |
|
|
|||||